Bryan, Garnier & Co restated their neutral rating on shares of AstraZeneca (LON:AZN) in a research note issued to investors on Friday, March 29th, ThisIsMoney.Co.Uk reports.
AZN has been the topic of several other reports. Barclays restated an overweight rating on shares of AstraZeneca in a report on Monday, January 21st. JPMorgan Chase & Co. restated a buy rating on shares of AstraZeneca in a report on Tuesday, January 22nd. Liberum Capital restated a hold rating on shares of AstraZeneca in a report on Friday, March 29th. Goldman Sachs Group set a GBX 4,080 ($53.31) target price on AstraZeneca and gave the stock a sell rating in a report on Tuesday, January 1st. Finally, Societe Generale boosted their target price on AstraZeneca from GBX 8,400 ($109.76) to GBX 8,500 ($111.07) and gave the stock a buy rating in a report on Wednesday, January 16th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have given a buy rating to the company. AstraZeneca presently has an average rating of Hold and a consensus price target of GBX 6,362.70 ($83.14).
Shares of AstraZeneca stock traded down GBX 99 ($1.29) on Friday, hitting GBX 5,815 ($75.98). 2,258,433 shares of the company were exchanged, compared to its average volume of 2,310,000. The stock has a market cap of $76.28 billion and a P/E ratio of 34.21. AstraZeneca has a 1-year low of GBX 4,928.50 ($64.40) and a 1-year high of GBX 6,540 ($85.46). The company has a debt-to-equity ratio of 136.31, a current ratio of 0.96 and a quick ratio of 0.71.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
See Also: Short Selling Stocks and Day Traders
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.